At a recent US FDA hearing Pfizer Inc. highlighted three types of product-related communications that could become more prevalent if the agency revises its regulatory framework governing industry communications about off-label uses.
In two of the cases, Pfizer delayed distributing information about uses within the approved indication due to a lack of...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
